VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline
VERAXA Biotech has reported new in vitro proof-of-concept data supporting its BiTAC-ADC technology, demonstrating selective activity against cancer cells while…